SWOG clinical trial number
SWOG-8955

Treatment of Stage D, Hormone Refractory Carcinoma of the Prostate with 5/Fluorouracil and Roferon-A®, Phase II

Closed
Phase
Accrual
58%
Published
Abbreviated Title
Treatment of Stage D, Hormone Refractory Carcinoma of the Prostate with 5/Fluorouracil and Roferon-A®, Phase II
Activated
06/15/1992
Closed
11/01/1993

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

1996

Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and roferon-A: A Southwest Oncology Group study.

ME Marshall;M Wolf;M O'Rourke;TC Barnett;ED Crawford Cancer Biotherapy & Radiopharmaceuticals 11(2):119-123

1994

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report.

M Hussain;M Wolf;E Marshall;ED Crawford;M Eisenberger Journal of Clinical Oncology 12(9):1868-1875

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase